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Abstract
Background: We have evaluated an attenuated Listeria monocytogenes (Lm) candidate vaccine vector in
nonhuman primates using a delivery regimen relying solely on oral vaccination. We sought to determine the
impact of prior Lm vector exposure on the development of new immune responses against HIV antigens.
Findings: Two groups of rhesus macaques one Lm naive, the other having documented prior Lm vector
exposures, were evaluated in response to oral inoculations of the same vector expressing recombinant HIV-1 Gag
protein. The efficacy of the Lm vector was determined by ELISA to assess the generation of anti-Listerial antibodies;
cellular responses were measured by HIV-Gag specific ELISpot assay. Our results show that prior Lm exposures did
not diminish the generation of de novo cellular responses against HIV, as compared to Listeria-naïve monkeys.
Moreover, empty vector exposures did not elicit potent antibody responses, consistent with the intracellular nature
of Lm.
Conclusions: The present study demonstrates in a pre-clinical vaccine model, that prior oral immunization with an
empty Lm vector does not diminish immunogenicity to Lm-expressed HIV genes. This work underscores the need
for the continued development of attenuated Lm as an orally deliverable vaccine.
Findings
More than 80% of new HIV acquisitions are through
mucosal routes, underscoring the importance of gener-
ating HIV-specific immunity by vaccination at these
sites [1]. A vaccine vector capable of inducing potent
mucosal immunity would represent a promising candi-
date for development [2].
Listeria monocytogenes (Lm) is a ubiquitous intracellu-
lar bacterium that has served as a model inducer of
innate and adaptive immunity to infection. Natural
infection with wild-type Lm typically initiates via the
oral route [3,4], and the breadth of immunity elicited by
Lm, combined with a natural predilection for the gut
has prompted their development as live vaccine vectors
[2,4-7]. Lm vectors have been shown to be effective in
both cancer [6,8,9] and in infectious disease settings
[7,9]. Despite the attractive features of Lm vectored anti-
gen delivery, there are potential obstacles to this
approach.
Anti-vector immunity represents an important hurdle
in the development of many recombinant vaccine-vector
systems. For example, anti-vector immunity has been
shown to markedly suppress the immunogenicity of
replication defective recombinant Adenovirus-5 based
strategies [10]. This problem has been circumvented
using vectors that display hexon antigen from low sero-
prevalence subtypes, or boosting with different subtype
vectors [10,11].
In the case of Lm, studies in murine and feline models
have assessed the impact of anti-Listerial immunity on
the generation of de-novo responses against Lm-
expressed gene inserts [12-14]. To date, clinical studies
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in approximately 60% of the cohort population [15].
Given the high likelihood of anti-Listerial immunity
within the populations of both developed and develop-
ing nations [16], this issue is needful of further
exploration.
In the current study, we update our progress on a Lis-
teria-based candidate vaccine against HIV. We extend
our immunogenicity studies by adopting a modified vac-
cine dose and delivery regimen relying solely on oral
vaccination.
Modified vaccine delivery
Two groups of macaques, one previously exposed to the
Lmdd vector (Group 1) and a Lm-naïve control (Group
2), were enrolled to test the immunogenicity of Lmdd-
HIV-gag [17]. We sought to assess safety and immuno-
genicity after modifying the regimen to oral only deliv-
ery of Lmdd-HIV-gag over 3 consecutive days (q.d. x3)
for priming and two consecutive boosts (Figure 1).
Phase I: immunization with empty vector Lmdd
Group1 monkeys (RSg-8, RUg-8 and RMh-8), received
Lmdd orally in conjunction with i.v. administration of
D-ala (Figure 1A). Repeated oral immunization with
empty Lmdd did not induce significant anti-Lm humoral
immunity (data not shown). However, marginally signifi-
cant proliferative responses (5-6 fold above background)
were detected in response to stimulation with LLO pep-
tides in all Group 1 animals prior to the start of Phase
II immunizations below (Figure 2).
Phase II: Lmdd-HIV-gag oral immunization of monkeys
with different Lmdd exposure histories
Thirty weeks after the last Lmdd boost (in Group 1
only), we enrolled 2 additional Lm naïve animals (RAm-
9, RHm-9). All monkeys then received a series of prime/
boost immunizations (q.d. x3) with Lmdd-HIV-gag (Fig-
ure 1B) and ELISpots were measured at multiple time
points as described. Briefly, PBMC were washed in sup-
plemented RPMI media and seeded onto plates (5 × 10
6
cells/ml) in the presence or absence of HIV-1 HXB2-
Gag overlapping peptides (NIH AIDS Research and
Reference Reagent Program) or Con A. After overnight
incubation, cells were removed and plates were incu-
bated with biotinylated anti-IFN-g antibody (BD Bios-
ciences), followed by incubation with anti-biotin
antibody labeled with enzyme. Spots were counted by
Immunospot software (BD Biosciences). Two weeks
after receiving oral priming with Lmdd-HIV-gag, all five
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Figure 1 Immunization schedule for administration of Lmdd or Lmdd-HIV-gag. A total of 5 individual monkeys were enrolled into 2
immunization groups: Group 1 (animals RMh-8, RSg-8, and RUg-8), received three oral inoculations of Lmdd empty vector alone during
experimental phase I; the doses were 1 × 10
12 organisms at week 0 followed by 3 × 10
12 organisms at weeks 6 and 19 (vaccination shown as
vertical arrows) (A). Group 2 (animals RAm-9 and RHm-9) were enrolled. In experimental phase II, both groups received Lmdd-HIV-gag orally in
phosphate-buffered saline (PBS) at wks 0, 6, and 19 at 3 × 10
12 organisms given for 3 consecutive days (q.d. x 3) depicted in (B). *The dosage (in
colony forming units/ml, CFU) administered at each time point is shown in parentheses for each group. All Lmdd-gag vaccinations were
preceded by oral administration of saturated sodium bicarbonate. D-ala (640 mg/kg) was co-administered intravenously before and after each
vaccine dose [17]. Lmdd inocula were also supplemented with D-ala (0.5 mg/ml in 20 ml) to ensure efficient bacterial replication.
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Page 2 of 7animals showed weak Gag-specific IFN-g ELISpot
responses. Background spots from medium-only wells
were subtracted from the wells with peptide stimulation.
Wells were considered positive when 3× more spots
were found than the average background with a mini-
mum of at least 25 spots and expressed as spot forming
units (SFU)/10
6 cells. Post-boost, positive ELISpot
responses were detectable in most animals. During the
course of the three vaccinations, all animals mounted
positive IFN-g ELISpot responses to Gag peptide stimu-
lation, although kinetics of peak responses appeared to
differ in each monkey (Figure 3A, B).
Significant Gag-specific proliferative responses (S.I.
values >10) were observed in 2 of 3 animals in Group 1,
and both Group 2 monkeys (Figure 3C). We also
observed significant proliferative responses to LLO pep-
tide stimulation within these animals (Figure 3D). These
results demonstrate that oral delivery of attenuated
Lmdd-HIV-gag is immunogenic and can induce Gag-
specific cellular immune responses, even in the presence
of multiple prior Lmdd exposures.
Anti-vector and anti-HIV Gag antibody responses
To test for the presence of anti-Lm antibodies, an
ELISA was employed using whole bacteria (Lm strain
12443) or recombinant LLO as described [17]. Antibody
titers are expressed as the end-point dilution that gave
an OD value determined as 2 SD above the mean
compared to the sera of 6 naïve monkeys. No increases
were observed during the course of the immunization in
any monkeys (Table 1 and 2). We also screened for
anti-Gag IgG responses by using ELISA plates (Fisher
Scientific Co, Pittsburgh, PA) coated with 0.5 μgo fH I V
Gag per well (Immunodiagnostic Inc. Woburn, MA).
Only one animal RSg-8, showed a weakly positive Gag-
specific titer (data not shown). The lack of significant
humoral responses in this model is not surprising; con-
sistent with both our earlier findings [17] and the inabil-
ity of Lm to elicit potent antibody responses via oral
infection routes.
Antigen recall after prolonged rest to orally delivered
Lmdd-HIV-gag
Next we sought to determine if any differences exist
(between Groups 1 and 2) in anamnestic responses
upon re-exposure to Lmdd-HIV-gag. Therefore at thir-
teen weeks after the last boost, all monkeys were orally
dosed using the Lmdd-HIV-gag dose as received pre-
viously (Figure 1B). Seven days later, all monkeys were
assessed for immune responses to Lm and HIV-Gag.
We assessed homing of T cells to mucosal sites by fol-
lowing the cell marker CD44 in conjunction with b-7
gut homing marker (BD Biosciences). Upon Gag peptide
stimulation, double-positive T cells were increased in all
five vaccinees. All five monkeys had at least 5% of the
total PBMC population that expressed both markers
upon Gag peptide stimulation. Monkey RMh-8 had an
unusually high response of nearly 20% of T cells expres-
sing both markers (Figure 4A).
We also determined the relative cytotoxic T lymphocyte
(CTL) activity by CD8
+CD107a
+ staining (BD Biosciences).
We observed a significant difference between groups 1 and
2 despite a relatively small sample size (Figure 4B). The
former group displayed a larger average increase in CTL
potential that may be associated with the increased num-
ber of Lm exposures. Alternatively, the demonstrated
increase in double positive cell percentages could be due
to significant levels of bystander T cell activation, or other
cells populations, that has been described in murine mod-
els of Lm infection [18]. Alternatively, differences in
genetic backgrounds between the two groups may account
for the observation.
Continued safety assessment
No adverse clinical effects were observed in any vacci-
nees during the course of the immunizations. Hematolo-
gical values and liver chemistries were unremarkable at
all time points. These results demonstrated that oral
inoculation of live attenuated Lmdd and i.v. D-ala
administration was safe and well tolerated in rhesus
macaques. Liver toxicity secondary to bacterial invasion
can be a serious complication of Lm infection. To assess
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Figure 2 Listeria-specific proliferative responses in immunized
macaques. PBMC from individual monkeys were tested for Listeria-
specific proliferative responses at the indicated time points after
inoculation with the empty Lmdd vector. Cells were cultured in
supplemented RPMI in the presence of HIV IIIB p55 Gag (2 μg/ml)
for 4 d. Cells were pulsed with 1 μCi per well of
3H-thymidine
(PerkinElmer, Boston, MA) for 18 h prior to harvesting. Thymidine
incorporation was assessed using a b-scintillation counter (Beckman
Coulter, Inc., Miami, FL). Results are expressed as stimulation index
(SI). To test for Lm-specific proliferative responses, whole Lm
bacteria (strain 12443) were used as described [17].
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Figure 3 Gag-specific IFN-gamma-secreting T cells from immunized macaques.( A) PBMC from individual monkeys were tested at the
indicated time points for Gag-specific IFN-gamma secreting T cells by in-vitro stimulation with overlapping HIV-Gag peptide pools. Vaccinations
were given at q.d. x3 at weeks 0, 6, and 19. (B) Mean IFN- g SFU over successive prime and boosting with Lmdd-HIV-gag. No significant
differences in ELISPOT generation were observed between groups of naïve rhesus macaques and those having prior oral Lm-vector exposure,
P = 0.4 (Wilcoxon rank sum test). (C) HIV-Gag specific proliferative responses in Lmdd-HIV-gag-immunized macaques. (D) Listeria LLO-specific
proliferative responses at the indicated time points during vaccination protocol. Stimulation indices (SI) were calculated as described. No
significant differences were observed for Gag- or LLO-specific stimulation, P = 0.8 and 0.4 respectively (Wilcoxon rank sum test).
Table 1 Serum Anti-Listeria IgG ELISA Titers
(whole Listeria)
Groups Weeks after Lmdd-HIV-gag immunization
Naive 0 6 12 19 21 23 33 34
RAm-9 200 200 200 200 200 200 200 400
RHm-9 200 200 200 200 200 200 200 200
Vector Control
RSg-8 200 400 400 400 400 400 400 800
RUg-8 200 200 200 400 800 800 800 800
RMh-8 400 400 400 400 800 400 400 400
Lmdd-HIV-gag plasma IgG titers at time points post immunization (0, 6, and
19 weeks). ELISAs were conducted using whole fixed Lm strain 12443, as
described [17].
Table 2 Serum Anti-Listerial IgG ELISA Titers (rLLO)
Groups Weeks after Lmdd-HIV-gag immunization
Naive 0 6 12 19 21 23 33 34
RAm-9 200 400 200 200 200 200 200 400
RHm-9 200 400 400 200 200 200 200 200
Vector Control
RSg-8 200 400 400 400 400 400 400 400
RUg-8 200 200 200 400 800 400 400 400
RMh-8 400 400 400 400 800 400 200 200
Anti-Listerial IgG ELISA conducted using recombinant His-tagged Listeriolysin
(LLO) as described [17].
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Page 4 of 7Lmdd-HIV-gag infiltration into the liver, tissue sections
were tested for recombinant Lm harboring the HIV-gag
expression cassette. Liver sections were collected (7
days after vaccination), and homogenized in RPMI
without antibiotics. Homogenates were clarified then
plated in triplicate onto BHI agar plates supplemented
with D-ala, erythromycin and streptomycin. Plates were
incubated at 37°C for 72 h prior to enumeration of
Lmdd-gag colonies. Lmdd-HIV-gag was not found in
the liver at 7-days post-inoculation, as measured by
plating on selective media specific for recombinant
Lmdd-HIV-gag.
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Figure 4 Expression of homing and degranulation markers in monkeys boosted after prolonged rest. PBMC were isolated from each
animal at the indicated time points following Lmdd-HIV-gag administration and tested for reactivity HIV-Gag peptides. (A) Percentage increase
in CD44-b7 populations in response to overlapping Gag-peptide. (B) Percentage increase in CD8-CD107a populations in response to overlapping
Gag-peptide.
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Page 5 of 7For practical reasons, the administration of any candi-
date HIV vaccine to large populations would be signifi-
cantly easier if delivered orally. In the present study, we
demonstrate in a rhesus model that a live-attenuated
Lm vector expressing HIV-gag is capable of eliciting
Gag-specific responses, even after multiple prior expo-
sures to the vector. Although similar results have been
shown in other animal models [12-14], our studies have
relied solely on oral delivery. As such, any occurrence of
anti-vector immunity might have been increased by
multiple dosing using the same route [17]. Despite this
potential issue, we observed no difference in Gag-speci-
fic ELISpot responses in monkeys with prior Lmdd
exposures. Similarly, Lm-vaccine boosting generated
modest levels of mucosal homing markers on peripheral
blood CD8
+ T cells.
While the levels of immunity generated in these ani-
mals was certainly not as high as with other vaccines,
we believe that at the time of measurement a significant
proportion of the response may have been already direc-
ted to mucosal sites. Later generation Lm vectors
[19-21] may be more effective than providing supple-
mental D-ala to vaccine preparations. Certainly the abil-
i t yo fL mt od i r e c ti m m u n er e s p o n s e st om u c o s a l
regions is an attractive feature of this vector [22]. Thus,
this technology should be considered a part of a hetero-
logous prime-boost. Furthermore, the lack of detectable
anti-Gag antibodies and low anti-Lm titers, while not
unexpected, could be increased by the selection of boost
modalities.
The potential benefits of live-vector vaccines must be
carefully weighted against safety and toxicity. Wild-type
Lm can pose a serious risk for pregnant women, neo-
nates and immunocompromised individuals [3,16,23].
As Lm is ubiquitous, the incidence of exposure to Lm
can be from moderate to high within many populations
[24], and therefore may pose an obstacle to Lm vaccine
development. However, the attenuated vector Lmdd,
used in the present study, was shown to be safe in adult
and neonatal mice [25]. Similarly, our data show that
orally administered Lmdd-HIV-gag was also safe in
adult monkeys, indicating limited bacterial invasion into
the liver, or complete clearance, by 7 days after boost
vaccination.
Our pilot results warrant the testing of attenuated
Lm vectors as part of an orally deliverable heterologous
prime-boost strategy. However, any future studies
should be suitably powered to assess if the current
findings are translated to larger populations. We
believe that the development of novel next generation
Lmdd-based vectors will facilitate that end by increased
immunogenicity while retaining a high margin of
safety.
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